Stryker announces the success of the simplified tender offer for outstanding shares of VEXIM

Kalamazoo, Michigan - December 11, 2017 - Stryker Corporation (NYSE:SYK) announced that the simplified public tender offer for the shares and BSAAR warrants of VEXIM, a French medical device company listed on the Euronext Growth stock exchange in France, has closed. VEXIM, headquartered in Balma, France, specializes in the development and sale of vertebral compression fracture (VCF) solutions.

The public tender offer was opened from November 16, 2017 to December 6, 2017. The results were published today by the French financial market authority (Autorité des marchés financiers, the "AMF"). Stryker, which already owned over 50% of the share capital and voting rights of VEXIM at the date of the filing of the public tender offer with the AMF, acquired an additional 4,036,406 shares during the offer period, as well as 226,520 BSAAR warrants that it has exercised for new shares of VEXIM. Stryker now holds 8,416,399 shares of VEXIM representing 92.19 % of its share capital and at least 91.56% of its voting rights.

Stryker is satisfied of this result and would like to thank all the shareholders and BSAAR warrant holders who tendered their securities into the Offer. Stryker is excited about the strength of VEXIM's differentiated product portfolio, management team, and European presence with Stryker's fast growing Neurotechnology and Spine businesses.

Forward-looking statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com

For media inquiries please contact:
Yin Becker, Stryker Corporation, 269-385-2600 or yin.becker@stryker.com

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Stryker Corporation via Globenewswire

Stryker (NYSE:SYK)
Historical Stock Chart
From Mar 2024 to Apr 2024